首页> 外文期刊>Leukemia Research: A Forum for Studies on Leukemia and Normal Hemopoiesis >Proliferation and apoptosis in acute and chronic leukemias and myelodysplastic syndrome.
【24h】

Proliferation and apoptosis in acute and chronic leukemias and myelodysplastic syndrome.

机译:急性和慢性白血病和骨髓增生综合征的增殖和凋亡。

获取原文
获取原文并翻译 | 示例
       

摘要

Clonal expansion of leukemic cells is thought to be due to proliferation in excess of apoptosis. To define and compare proliferation and apoptosis between various leukemias and myelodysplastic syndrome (MDS), we measured proliferating cell nuclear antigen (PCNA) and bromodeoxyuridine (BrdU) incorporation as surrogate markers for proliferation and caspase 3 activity and annexin V surface binding as surrogate markers for activation of the apoptotic cascade in patients with MDS, chronic myelomonocytic leukemia (CMML), acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), and chronic myeloid leukemia (CML). We found high proliferation in bone marrow cells from MDS and CMML as measured by PCNA and BrdU incorporation. The lowest level of proliferation was found in CLL. Apoptosis was also highest in MDS and CMML as measured by annexin V and caspase 3 activity. Unexpectedly, we found no significant difference in proliferation in bone marrow CD34+ cells from various leukemias or MDS. Apoptosis was significantly higher in bone marrow CD34+ cells from MDS and CML in chronic phase as compared to CD34+ cells from AML patients. Our results illustrate differences in proliferation and apoptosis between acute and chronic leukemias and MDS. These differences may have diagnostic and therapeutic implications.
机译:白血病细胞的克隆膨胀被认为是由于凋亡过多的增殖所致。为了定义和比较各种白血病和骨髓增生综合征(MDS)之间的增殖和凋亡,我们测量了增殖细胞核抗原(PCNA)和溴脱氧尿苷(BRDU)掺入作为替代标记物的替代标记物,用于增殖和caspase 3活性和nendenxin v表面替代标记的替代标记。 MDS患者,慢性脊髓细胞性白血病(CMML),急性髓细胞性白血病(AML),急性淋巴细胞白血病(ALL),慢性淋巴细胞性白血病(CLL)和慢性骨髓性白血病(CML)激活凋亡级联反应。我们发现,通过PCNA和BRDU掺入测量的MDS和CMML的骨髓细胞中的高增殖。在CLL中发现了最低的增殖水平。通过膜联蛋白V和caspase 3活性测量,MDS和CMML的凋亡也最高。出乎意料的是,我们发现来自各种白血病或MD的骨髓CD34+细胞的增殖没有显着差异。与AML患者的CD34+细胞相比,在慢性期MDS和CML的骨髓CD34+细胞中的凋亡明显更高。我们的结果说明了急性和慢性白血病和MDS之间的增殖和凋亡差异。这些差异可能具有诊断性和治疗性。

著录项

相似文献

  • 外文文献
  • 中文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号